‘2024 Is The Year Of Financial Progression,’ Says Fresenius As Biosimilars Revenues Jump 102%

With an “attractive biosimilar product portfolio,” Fresenius marked a strong second quarter in its biopharma business, while the generic pharma segment remained flat, but is still “a source of continued success.”